vs
Side-by-side financial comparison of Third Coast Bancshares, Inc. (TCBX) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Third Coast Bancshares, Inc. is the larger business by last-quarter revenue ($57.7M vs $57.2M, roughly 1.0× Vanda Pharmaceuticals Inc.). Third Coast Bancshares, Inc. runs the higher net margin — 28.4% vs -246.8%, a 275.1% gap on every dollar of revenue. Over the past eight quarters, Third Coast Bancshares, Inc.'s revenue compounded faster (17.5% CAGR vs 9.8%).
Third Coast Bancshares, Inc. is a regional financial holding company headquartered in the U.S. Gulf Coast region. It provides a full suite of commercial and retail banking services including deposit products, business and consumer loans, mortgage services, and wealth management solutions, serving local small and medium-sized enterprises, individual consumers, and community clients across Texas and surrounding areas.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
TCBX vs VNDA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.7M | $57.2M |
| Net Profit | $16.4M | $-141.2M |
| Gross Margin | — | — |
| Operating Margin | — | -70.5% |
| Net Margin | 28.4% | -246.8% |
| Revenue YoY | — | 7.6% |
| Net Profit YoY | 20.5% | -2774.3% |
| EPS (diluted) | $0.88 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $57.7M | — | ||
| Q4 25 | $56.5M | $57.2M | ||
| Q3 25 | $54.5M | $56.3M | ||
| Q2 25 | $52.0M | $52.6M | ||
| Q1 25 | $45.9M | $50.0M | ||
| Q4 24 | $46.3M | $53.2M | ||
| Q3 24 | $42.9M | $47.7M | ||
| Q2 24 | $41.7M | $50.5M |
| Q1 26 | $16.4M | — | ||
| Q4 25 | $17.9M | $-141.2M | ||
| Q3 25 | $18.1M | $-22.6M | ||
| Q2 25 | $16.7M | $-27.2M | ||
| Q1 25 | $13.6M | $-29.5M | ||
| Q4 24 | $13.7M | $-4.9M | ||
| Q3 24 | $12.8M | $-5.3M | ||
| Q2 24 | $10.8M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | 38.1% | -70.5% | ||
| Q3 25 | 41.9% | -55.6% | ||
| Q2 25 | 40.5% | -73.2% | ||
| Q1 25 | 37.8% | -82.0% | ||
| Q4 24 | 38.7% | -19.3% | ||
| Q3 24 | 37.9% | -23.1% | ||
| Q2 24 | 34.1% | -20.1% |
| Q1 26 | 28.4% | — | ||
| Q4 25 | 31.7% | -246.8% | ||
| Q3 25 | 33.1% | -40.1% | ||
| Q2 25 | 32.2% | -51.7% | ||
| Q1 25 | 29.6% | -58.9% | ||
| Q4 24 | 29.7% | -9.2% | ||
| Q3 24 | 29.8% | -11.2% | ||
| Q2 24 | 25.9% | -9.0% |
| Q1 26 | $0.88 | — | ||
| Q4 25 | $1.02 | $-2.40 | ||
| Q3 25 | $1.03 | $-0.38 | ||
| Q2 25 | $0.96 | $-0.46 | ||
| Q1 25 | $0.78 | $-0.50 | ||
| Q4 24 | $0.80 | $-0.09 | ||
| Q3 24 | $0.74 | $-0.09 | ||
| Q2 24 | $0.63 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $650.5M | $327.2M |
| Total Assets | $6.6B | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $175.2M | $84.9M | ||
| Q3 25 | $116.4M | $70.0M | ||
| Q2 25 | $113.1M | $81.0M | ||
| Q1 25 | $219.0M | $111.8M | ||
| Q4 24 | $371.2M | $102.3M | ||
| Q3 24 | $258.2M | $100.5M | ||
| Q2 24 | $241.8M | $103.0M |
| Q1 26 | $650.5M | — | ||
| Q4 25 | $531.0M | $327.2M | ||
| Q3 25 | $513.8M | $466.0M | ||
| Q2 25 | $496.1M | $486.3M | ||
| Q1 25 | $479.8M | $511.4M | ||
| Q4 24 | $460.7M | $538.5M | ||
| Q3 24 | $450.5M | $541.2M | ||
| Q2 24 | $435.0M | $542.5M |
| Q1 26 | $6.6B | — | ||
| Q4 25 | $5.3B | $488.9M | ||
| Q3 25 | $5.1B | $601.1M | ||
| Q2 25 | $4.9B | $624.7M | ||
| Q1 25 | $4.9B | $631.9M | ||
| Q4 24 | $4.9B | $656.2M | ||
| Q3 24 | $4.6B | $645.1M | ||
| Q2 24 | $4.5B | $651.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-29.4M |
| Free Cash FlowOCF − Capex | — | $-29.5M |
| FCF MarginFCF / Revenue | — | -51.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $50.8M | $-29.4M | ||
| Q3 25 | $20.7M | $-31.6M | ||
| Q2 25 | $13.9M | $-15.3M | ||
| Q1 25 | $10.5M | $-33.1M | ||
| Q4 24 | $35.1M | $-1.8M | ||
| Q3 24 | $22.0M | $-14.6M | ||
| Q2 24 | $7.3M | $-6.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-29.5M | ||
| Q3 25 | — | $-31.8M | ||
| Q2 25 | — | $-15.6M | ||
| Q1 25 | — | $-33.6M | ||
| Q4 24 | $33.4M | $-2.0M | ||
| Q3 24 | — | $-14.7M | ||
| Q2 24 | — | $-7.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | -51.6% | ||
| Q3 25 | — | -56.5% | ||
| Q2 25 | — | -29.6% | ||
| Q1 25 | — | -67.1% | ||
| Q4 24 | 72.1% | -3.8% | ||
| Q3 24 | — | -30.9% | ||
| Q2 24 | — | -13.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | 3.8% | 0.4% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 2.84× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 0.77× | — | ||
| Q4 24 | 2.56× | — | ||
| Q3 24 | 1.72× | — | ||
| Q2 24 | 0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TCBX
| Net Interest Income | $53.6M | 93% |
| Noninterest Income | $4.0M | 7% |
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
